These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7853578)

  • 1. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
    Bouffioux C; Kurth KH; Bono A; Oosterlinck W; Kruger CB; De Pauw M; Sylvester R
    J Urol; 1995 Mar; 153(3 Pt 2):934-41. PubMed ID: 7853578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
    Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
    J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
    Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
    Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
    Bouffioux C; Denis L; Oosterlinck W; Viggiano G; Vergison B; Keuppens F; De Pauw M; Sylvester R; Cheuvart B
    J Urol; 1992 Aug; 148(2 Pt 1):297-301. PubMed ID: 1635122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
    Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
    Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
    Ferraris V; Serao A; Buffa G
    Minerva Urol Nefrol; 1999 Jun; 51(2):95-101. PubMed ID: 10429419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer.
    Flamm J
    Eur Urol; 1990; 17(2):119-24. PubMed ID: 2178939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a randomized, double blind prospective study of intravesical chemoprophylaxis with 2 drugs: adriamycin and mitomycin; and 2 ways of initiating the instillations: early and late. Effect on recurrence and progression].
    Iborra Juan I; Ricos Torrent JV; Monrós Lliso JL; Dumont Martínez R; Casanova Ramón-Borja J; Solsona Narbón E
    Arch Esp Urol; 1992 Dec; 45(10):1001-7. PubMed ID: 1294028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
    Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
    J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
    da Silva FC; Ferrito F; Brandão T; Santos A
    Eur Urol; 1992; 21(1):42-4. PubMed ID: 1606981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
    Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
    Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
    Schwaibold H; Pichlmeier U; Klingenberger HJ; Huland H
    Eur Urol; 1997; 31(2):153-9. PubMed ID: 9076457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.